Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2021. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of March 31, 2021, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital (as of March 31, 2021): 5,386,594,390 Ordinary Shares of 25 pence each.
- Treasury Shares: 355,205,950 Ordinary Shares.
- Total Voting Rights: 5,031,388,440.
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,031,388,440) to determine if disclosure thresholds for shareholding interests have been met.
- Confirm the number of shares held in Treasury (355,205,950) which are excluded from the voting rights count.
- Note that this filing does not contain operational or financial results for the period.